Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.
about
Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.
@en
Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.
@nl
type
label
Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.
@en
Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.
@nl
prefLabel
Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.
@en
Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.
@nl
P2093
P2860
P1433
P1476
Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.
@en
P2093
Alessandro Ciresi
Enrica Vigneri
Felicia Pantò
Stefano Radellini
P2860
P2888
P304
P356
10.1007/S13300-017-0338-4
P577
2017-11-14T00:00:00Z